Advanced colorectal cancer: Anti-interleukin-1 alpha antibody MABp1 improves outcomes significantly over placebo

A novel anti-interleukin 1-alpha antibody has shown a significant impact on symptoms, and a high level of safety and tolerability in patients with advanced colorectal cancer, according to phase III data.